ATLANTA--(BUSINESS WIRE)--March 11, 2026--
Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the fourth quarter and full year ended December 31, 2025. The Company also raised its full-year 2026 Adjusted EBITDA guidance.
Fourth Quarter Financial Results
-- Revenue of $397.6 million, up 17% year-over-year with organic growth of
12%.
-- Residents served ended the quarter at approximately 205,000, up 10%
year-over-year.
-- Net Income of $21.3 million, up 81% from $11.8 million in the
prior-year period.
-- Adjusted EBITDA of $39.5 million, up 53% year over year.
-- Diluted EPS of $0.33 for the quarter, with Adjusted EPS of $0.37.1
Full Year Financial Results
-- Revenue of $1.45 billion, up 18% from $1.23 billion in the prior year
period with organic growth of 13%.
-- Net Income (loss) of $49.0 million, compared to ($71.0) million in
2024.
-- Adjusted EBITDA of $115.1 million, up 27% compared to $90.8 million
year over year.
-- Diluted EPS of $0.78, with Adjusted EPS of $1.071.
-- Cash and cash equivalents totaled $65.6 million at year end, up from
$4.7 million at the end of 2024.
CEO Commentary
"2025 was a year of broad-based execution and disciplined investment, with results that exceeded our expectations across resident, revenue, and Adjusted EBITDA growth," said Fred Burke, President and CEO. "These results underscore the scalability of our platform and the dedication of our teams, who continue to deliver high-quality service and meaningful value to the residents and facility partners we serve."
Burke continued, "We exited the year with strong momentum and are accordingly raising our outlook for 2026 Adjusted EBITDA in a measured manner, consistent with our philosophy of guiding to what we can clearly see. A portion of the upside we experienced in the fourth quarter relative to our prior guidance reflects favorable payor dynamics and normal quarter-to-quarter variability, which we have not incorporated into our outlook. We view the underlying run rate of the business exiting 2025 as generating approximately $110 million of Adjusted EBITDA, and are raising our 2026 outlook on that basis. As we enter the first quarter under the initial phase of new IRA drug pricing changes, we are maintaining our 2026 revenue outlook provided in mid-January. We remain confident in the durability of our operating model and our ability to deliver sustained, long-term value for our shareholders."
____________________________ (1) Diluted EPS and Adjusted EPS include dilutive shares related to restricted stock units and unvested Class A and Class B common stock. See reconciliation of Adjusted EPS to Diluted EPS, the most directly comparable GAAP measure, below.
FY 2026 Outlook -- Raising Adjusted EBITDA Guidance
The guidance below excludes future acquisitions.
Updated Guidance Previous Guidance
--------------- ----------------------------- ------------------------------
Revenue $1.40 billion -- $1.42 $1.40 billion -- $1.42 billion
billion
--------------- ----------------------------- ------------------------------
Adjusted EBITDA $ 120 million -- $124 million $115 million - $118 million
--------------- ----------------------------- ------------------------------
Operational and Strategic Highlights
Acquisitions & Greenfields
During the quarter, Guardian acquired North Ridge Pharmacy, located in Missoula, Montana, bringing our full-service pharmacy count to 54.
Vaccine Clinics
Vaccine prescription volumes increased 3% year over year in the fourth quarter, while full-year prescription volumes increased 9%. Importantly, profitability improved compared to the prior year, driven by stronger purchasing, reimbursement, and labor economics as well as solid operational execution. In total, we vaccinated more than 120,000 residents in 2025.
Capital Efficiency and Liquidity
Guardian delivered an annualized return on equity(2) of approximately 27% in 2025, reflecting the capital efficiency of the business. The Company ended the year with a strong liquidity position, including $65.6 million of cash and cash equivalents with no long-term debt outstanding under its $75 million credit facility.
____________________________ (2) Return on equity is calculated as Net Income of $49.0 million divided by Average Total Equity during the period of $184.0 million. Average Total Equity is calculated based on Total Equity of $150.0 million as of December 31, 2024 and Total Equity of $217.9 million as of December 31, 2025.
Conference Call Details
Guardian will host a conference call to discuss these results today at 4:30 pm ET. The call can be accessed live by dialing (646) 564-2877 for U.S. participants, or +1 (800) 549-8228 for international participants, and referencing conference ID "93533," or via audio webcast at https://investors.guardianpharmacy.com
About Guardian Pharmacy Services
Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies. Through its locally--based business model, Guardian partners with long-term care facilities ("LTCFs") to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of 61 pharmacies, 54 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 205,000 residents (as of December 31, 2025).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are forward-looking. These statements are often, but not always, made through the use of words such as "aims," "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "outlook," "plans, " "projects," "seeks," "should," "will," "would," and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to effectively execute our business strategies, implement new initiatives and improve efficiency; our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; our relationships with pharmaceutical wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees and business and on our supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by limiting pharmacy reimbursements; changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental inquiries; our ability to maintain the security and integrity of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense; and volatility of our stock price. We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the "Risk Factors" section contained in our most recent Annual Report on Form 10-K, which report is publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management's views as of the date hereof. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.
Additional Information
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings. Copies of our reports are available on our website at no expense at investors.guardianpharmacy.com and through the SEC's website at www.sec.gov.
Use of Non-GAAP Financial Measures
To supplement the results presented in our consolidated financial statements in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A, which are financial measures not based on any standardized methodology prescribed by GAAP.
We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, acquisition accounting adjustments, certain legal and regulatory items, financing-related and other activities, payor-reimbursement matters, and certain tax matters related to the Corporate Reorganization and IPO.
We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc. before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, the income tax impact of the adjustments, and certain tax matters related to the Corporate Reorganization and IPO.
We define Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A and Class B common stock.
We define Adjusted SG&A as GAAP selling, general, and administrative expenses adjusted to exclude the impact of share-based compensation, expenses relating to certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.
Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Adjusted SG&A may not be the same as, or comparable to, similarly titled measures used by other companies.
We use Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.
There are a number of limitations related to the use of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A rather than the most directly comparable GAAP financial measure, including:
-- Adjusted EBITDA does not reflect interest and income tax payments that
represent a reduction in cash available to us;
-- Depreciation and amortization are non-cash charges and the assets being
depreciated may have to be replaced in the future, and Adjusted EBITDA
does not reflect cash capital expenditure requirements for such
replacements or for new capital expenditure requirements;
-- Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not reflect
changes in, or cash requirements for, our working capital needs;
-- Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A
do not consider the impact of share-based compensation; and
-- Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A
exclude the impact of certain legal and regulatory items, and
payor-reimbursement matters which can affect our current and future cash
requirements.
Because of these limitations, Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A alongside other financial measures, including net income, diluted EPS, GAAP selling, general, and administrative expense and our other financial results presented in accordance with GAAP.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, are set forth below.
Guardian has not provided a quantitative reconciliation of forecasted adjusted EBITDA, which is a non-GAAP financial measure, to forecasted net income within this release because Guardian is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items. These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December 31,
(In thousands, except share amounts) 2024 2025
------- -------
Assets
Current assets:
Cash and cash equivalents $ 4,660 $ 65,619
Accounts receivable, net 97,153 101,614
Inventories 40,550 43,359
Other current assets 9,622 11,042
------- -------
Total current assets 151,985 221,634
Property and equipment, net 49,883 55,522
Intangible assets, net 14,912 18,475
Goodwill 69,296 79,743
Operating lease right-of-use assets 29,079 34,649
Deferred tax assets 5,272 2,199
Other assets 383 436
------- -------
Total assets $320,810 $412,658
======= =======
Liabilities and equity
Current liabilities:
Accounts payable $102,420 $116,206
Accrued compensation 14,430 15,048
Operating leases, current portion 6,836 7,150
Other current liabilities 20,435 22,299
------- -------
Total current liabilities 144,121 160,703
Operating leases, net of current portion 23,297 29,992
Other liabilities 3,416 4,039
------- -------
Total liabilities $170,834 $194,734
======= =======
Commitments and contingencies (see Note 9)
Equity:
Members' equity -- --
Class A common stock- 700,000,000 shares
authorized, par value $0.001; 9,200,000 and
36,253,744 shares issued and outstanding as of
December 31, 2024 and December 31, 2025,
respectively 9 36
Class B common stock- 100,000,000 shares
authorized, par value $0.001; 54,087,158 and
27,066,890 shares issued and outstanding as of
December 31, 2024 and December 31, 2025,
respectively 54 27
Additional paid-in capital 125,484 139,353
Retained earnings 17,124 66,343
Non-controlling interests 7,305 12,165
------- -------
Total equity 149,976 217,924
------- -------
Total liabilities and equity $320,810 $412,658
======= =======
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended Year Ended
December 31, December 31,
-------------------------- ----------------------------
(In thousands,
except share and
per share
amounts) 2024 2025 2024 2025
---------- ---------- ---------- ----------
Revenues $ 338,569 $ 397,616 $ 1,228,409 $ 1,448,685
Cost of goods
sold 271,465 312,114 984,038 1,155,967
---------- ---------- ---------- ----------
Gross profit 67,104 85,502 244,371 292,718
Selling, general,
and
administrative
expenses 50,349 54,740 307,291 220,017
---------- ---------- ---------- ----------
Operating income
(loss) 16,755 30,762 (62,920) 72,701
Other expenses
(income):
Interest
expense 421 163 3,278 665
Other expense
(income),
net 113 (500) 279 (1,387)
---------- ---------- ---------- ----------
Total other
expenses
(income) 534 (337) 3,557 (722)
---------- ---------- ---------- ----------
--
Income (loss)
before income
taxes 16,221 31,099 (66,477) 73,423
Provision for
income taxes 4,380 9,834 4,556 24,465
---------- ---------- ---------- ----------
Net income (loss) 11,841 21,265 (71,033) 48,958
---------- ---------- ---------- ----------
Less net income
attributable to
Guardian
Pharmacy, LLC
prior to the
Corporate
Reorganization -- 22,760 --
Less net income
(loss)
attributable to
non-controlling
interests (102) 342 16,254 (261)
---------- ---------- ---------- ----------
Net income (loss)
attributable to
Guardian
Pharmacy
Services, Inc. $ 11,943 $ 20,923 $ (110,047) $ 49,219
========== ========== ========== ==========
Net income (loss)
per share of
Class A and Class
B common stock
Basic $ 0.19 $ 0.33 $ (1.77) $ 0.79
Diluted $ 0.19 $ 0.33 $ (1.77) $ 0.78
Weighted-average
Class A and Class
B common shares
outstanding
Basic 62,043,311 63,320,634 62,005,811 62,386,253
Diluted 62,724,108 63,617,708 62,005,811 63,297,123
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
-----------------------------
(In thousands) 2024 2025
---------- --------
Operating activities
Net income (loss) $ (71,033) $ 48,958
Adjustments to reconcile net income
(loss) to net cash provided by operating
activities:
Depreciation and amortization 19,772 22,335
Share-based compensation expense 131,490 13,850
Provision for losses on accounts
receivable 6,370 4,581
Change in deferred tax asset -- 3,074
Other 767 1,075
Changes in operating assets and
liabilities:
Accounts receivable (25,485) (8,553)
Inventories (1,151) (877)
Other current assets (1,979) (2,482)
Accounts payable 13,230 16,398
Accrued compensation (2,967) 618
Other operating liabilities (11,054) 1,316
---------- --------
Net cash provided by operating activities 57,960 100,293
Investing activities
Purchases of property and equipment (16,368) (19,583)
Payment for acquisitions (14,710) (13,416)
Other 671 736
---------- --------
Net cash used in investing activities (30,407) (32,263)
Financing activities
Proceeds from equity offering, net of
underwriter fees 119,784 29,039
Repurchase of outstanding Class A common
stock -- (29,039)
Payments of equity offering costs (4,157) (1,594)
Payments to Class B common stock
stockholders (55,176) --
Borrowings from notes payable 15,000 --
Repayment of notes payable (38,000) (497)
Borrowings from line of credit 189,300 --
Repayments of line of credit (198,300) --
Principal payments on finance lease
obligations (4,481) (4,483)
Payments related to acquisitions -- (2,509)
Contributions from non-controlling
interests 2,758 1,970
Distributions to non-controlling
interests (14,463) (458)
Member distributions (35,750) --
Other (160) 500
---------- --------
Net cash used in financing activities (23,645) (7,071)
Net change in cash and cash equivalents 3,908 60,959
Cash and cash equivalents, beginning of
period 752 4,660
---------- --------
Cash and cash equivalents, end of period $ 4,660 $ 65,619
========== ========
Supplemental disclosure of cash flow
information
Cash paid during the year for interest $ 3,121 $ 650
========== ========
Cash paid during the year for income
taxes $ -- $ 21,541
========== ========
Supplemental disclosure of non-cash
investing and financing activities
Purchases of property and equipment
through finance leases $ 3,529 $ 4,941
========== ========
Accrued and capitalized offering costs
recorded to additional paid-in capital $ 8,866 $ --
========== ========
Non-cash equity contributions from
non-controlling members $ 5,604 $ 3,609
========== ========
GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP GAAP FINANCIAL MEASURES
Three Months Ended December 31, Year Ended December 31,
-------------------------------- ------------------------------
(in thousands) 2024 2025 2024 2025
---------- ---------- -------- ----------
Net income (loss) $ 11,841 21,265 $ (71,033) 48,958
Add:
Interest expense
(income), net 421 (215) 3,278 (418)
Depreciation and
amortization 5,153 5,741 19,772 22,335
Provision for income
taxes 4,380 9,834 4,556 24,465
---------- ---------- -------- ----------
EBITDA $ 21,795 $ 36,625 $ (43,427) $ 95,340
---------- ---------- -------- ----------
Share-based
compensation (1) 3,461 1,080 131,490 13,850
Certain legal &
other regulatory
matters (2) 181 37 3,988 1,094
Financing-related
and other
activities (3) 453 251 453 2,175
Payor-reimbursement
matters (4) -- $ 1,493 (1,670) $ 2,686
---------- ---------- -------- ----------
Adjusted EBITDA $ 25,890 $ 39,486 $ 90,834 $ 115,145
========== ========== ======== ==========
Net income as a
percentage of
revenue 3.5% 5.3% (5.8)% 3.4%
========== ========== ======== ==========
Adjusted EBITDA as a
percentage of
revenue 7.6% 9.9% 7.4% 7.9%
========== ========== ======== ==========
Net Income (loss)
attributable to
Guardian Pharmacy
Services, Inc. 11,943 20,923 (110,047) 49,219
Share-based
compensation (1) 3,461 1,080 N/M 13,850
Certain legal &
other regulatory
matters (2) 181 37 N/M 1,094
Financing-related
and other
activities (3) 453 251 N/M 2,175
Payor-reimbursement
matters (4) -- 1,493 N/M 2,686
Acquisition-related
intangible asset
amortization (5) 868 971 N/M 3,658
Income tax impact of
adjustments (7) (1,340) (1,115) N/M (6,969)
Certain tax matters
related to
Corporate
Reorganization and
IPO (6) -- -- -- 1,725
---------- ---------- -------- ----------
Adjusted net income $ 15,566 $ 23,640 N/M (8) $ 67,438
========== ========== ============= ==========
Weighted average
common shares
outstanding used in
calculating diluted
U.S. GAAP net income
per share 62,724,108 63,617,708 N/A 63,297,123
Weighted average
common shares
outstanding used in
calculating diluted
Non-GAAP net income
per share 62,724,108 63,617,708 N/M 63,297,123
Diluted EPS $ 0.19 $ 0.33 (1.77) $ 0.78
Adjusted EPS 0.25 $ 0.37 N/M (8) $ 1.07
GAAP selling, general,
and administrative
expenses 50,349 $ 54,740 307,291 220,017
Subtract:
Share-based
compensation (1) 3,461 1,080 131,490 13,850
Certain legal &
other regulatory
matters (2) 181 37 3,988 1,094
Financing-related
and other
activities (3) 453 251 453 2,175
Payor-reimbursement
matters (4) $ -- 1,493 $ -- 4,316
---------- ---------- -------- ----------
Adjusted SG&A $ 46,254 $ 51,879 $ 171,360 $ 198,582
========== ========== ======== ==========
GAAP selling, general,
and administrative
expenses as a
percentage of
revenue 14.9% 13.8% 25.0% 15.2%
========== ========== ======== ==========
Adjusted SG&A as a
percentage of
revenue 13.7% 13.0% 13.9% 13.7%
========== ========== ======== ==========
(1) Prior to the Corporate Reorganization and IPO, our share-based
compensation expense primarily represented non-cash recognition of
changes in the value of Restricted Interest Unit awards, which had
historically been recorded as a liability using a cash settlement
methodology as calculated on a quarterly basis. In connection with
the Corporate Reorganization and IPO, certain Restricted Interest
Unit awards were modified, resulting in incremental share-based
compensation expense of $125.7 million during the year ended December
31,2024, based on the fair value of the modified awards. Share-based
compensation expense subsequent to the Corporate Reorganization and
IPO and for the year ended December 31, 2025 relates to
equity-classified awards.
(2) Represents non-recurring attorney's fees, settlement costs and other
expenses associated with certain legal proceedings. The Company
excludes such charges when evaluating operating performance because
it does not incur such charges on a predictable basis and exclusion
allows for consistent evaluation of operations.
(3) Represents non-recurring costs associated with various
financing-related activities and costs to transition to a public
company.
(4) Represents non-recurring proceeds, recorded as revenue, and legal
expenses, recorded as selling, general and administrative expenses,
associated with payor reimbursement matters.
Proceeds received associated with payor reimbursement matters,
recorded as revenue, were $0.0 million and $1.6 million during the
three months and year ended December 31, 2025, respectively, and $0.0
million and $1.7 million during the three months and year ended
December 31, 2024, respectively.
Legal expenses associated with payor reimbursement matters, recorded
as selling, general and administrative expenses, during the three
months and year ended December 31, 2025 were $1.5 million and $4.3
million, respectively and $0.0 million during the three months and
year ended December 31, 2024.
(5) Represents amortization expense associated with the
acquisition-related intangible assets, such as customer lists and
trademarks.
(6) Represents non-recurring income tax expense associated with the
Corporate Reorganization and IPO. The Company excludes such charges
when evaluating operating performance because it does not incur such
charges on a predictable basis and exclusion allows for consistent
evaluation of operations.
(7) Represents the income tax impact of non-GAAP adjustments, calculated
using the estimated tax rate for the respective non-GAAP adjustment.
(8) Adjusted net income and Adjusted EPS are not presented for the year
ended December 31, 2024, as the net income attributable to Guardian
Pharmacy Services, Inc. during that period only includes net income
for the period subsequent to our IPO on September 27, 2024. As such,
adjusted net income and adjusted EPS are not meaningful for these
periods.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260311592107/en/
CONTACT: Investor Contact:
Ashley Stockton
Vice President, Investor Relations
IR@guardianpharmacy.net
(END) Dow Jones Newswires
March 11, 2026 16:05 ET (20:05 GMT)